<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208325</url>
  </required_header>
  <id_info>
    <org_study_id>CT 9923</org_study_id>
    <nct_id>NCT00208325</nct_id>
  </id_info>
  <brief_title>PFC Sigma Fixed and Mobile Knee Study</brief_title>
  <official_title>Clinical Evaluation of the P.F.C. Sigma (Fixed Bearing) and P.F.C. Sigma RP (Mobile Bearing) Total Knee Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DePuy International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DePuy International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this investigation is to evaluate the performance (in terms of
      post-operative active range of motion at one year) of the P.F.C. Sigma and P.F.C. Sigma
      Rotating Platform total knee systems in clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this investigation are:To evaluate the performance of the P.F.C.
      Sigma and P.F.C. Sigma Rotating Platform total knee systems in clinical practice. To evaluate
      the impact of patellar resurfacing on the performance of the P.F.C. Sigma and the P.F.C.
      Sigma Rotating Platform total knee systems. To evaluate the impact of Posterior Cruciate
      Ligament (PCL) sacrifice or retention on the performance of the P.F.C. Sigma and the P.F.C.
      Sigma Rotating Platform total knee systems.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated at the point the primary endpoint and early milestones were reached
    and because long term outcomes were available from other sources
  </why_stopped>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>1 year</time_frame>
    <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>1 year</time_frame>
    <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 1 year</time_frame>
    <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 1 year</time_frame>
    <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Range of Motion From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Range of Motion From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Range of Motion From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Oxford Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Oxford Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Oxford Knee Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in American Knee Society Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in American Knee Society Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in American Knee Society Knee Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in American Knee Society Function Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in American Knee Society Function Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in American Knee Society Function Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>2 years</time_frame>
    <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>2 years</time_frame>
    <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>2 years</time_frame>
    <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>2 years</time_frame>
    <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in SF-12 Physical Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in SF-12 Physical Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in SF-12 Physical Health Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in SF-12 Mental Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in SF-12 Mental Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in SF-12 Mental Health Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>2 years</time_frame>
    <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>2 years</time_frame>
    <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Lateral Release Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>Operative</time_frame>
    <description>Lateral release is a surgical procedure to release tight capsular structures (lateral retinaculum) on the outside of the kneecap (patella). It is performed during knee surgery and allows the kneecap to move smoothly in the center of the knee. Rate information was collected at time of study surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Lateral Release Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>Operative</time_frame>
    <description>Lateral release is a surgical procedure to release tight capsular structures (lateral retinaculum) on the outside of the kneecap (patella). It is performed during knee surgery and allows the kneecap to move smoothly in the center of the knee. Rate information was collected at time of study surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>2 Years</time_frame>
    <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</measure>
    <time_frame>2 Years</time_frame>
    <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>2 Years</time_frame>
    <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>2 Years</time_frame>
    <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>2 Years</time_frame>
    <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>2 Years</time_frame>
    <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>5 Years</time_frame>
    <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 2 years</time_frame>
    <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</measure>
    <time_frame>Change from pre-op to 5 years</time_frame>
    <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">754</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>PFC Sigma Fixed Bearing PCL Sacrificed</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFC Sigma RP PCL Sacrificed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFC Sigma Fixed Bearing PCL Retained</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFC Sigma RP PCL Retained</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>P.F.C Sigma Fixed Bearing total knee system</intervention_name>
    <description>Orthopaedic implant for total knee replacement</description>
    <arm_group_label>PFC Sigma Fixed Bearing PCL Sacrificed</arm_group_label>
    <arm_group_label>PFC Sigma Fixed Bearing PCL Retained</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>P.F.C Sigma RP Mobile Bearing knee system</intervention_name>
    <description>Orthopaedic implant for total knee replacement</description>
    <arm_group_label>PFC Sigma RP PCL Sacrificed</arm_group_label>
    <arm_group_label>PFC Sigma RP PCL Retained</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects may be recruited to the evaluation.

          2. Age - there are no restrictions relating to age of the patient. The patient's age must
             be considered suitable by the clinical investigator for a bi-compartmental or
             tri-compartmental knee arthroplasty using either of the two systems available in the
             evaluation.

          3. Subjects who are able to give voluntary, written informed consent to participate in
             this investigation and from whom consent has been obtained.

          4. Subjects who, in the opinion of the Investigator, are able to understand this
             investigation, co-operate with the investigational procedures and are willing to
             return to the hospital for all the required post-operative follow-ups.

          5. Subjects who require a bi-compartmental or tri-compartmental knee arthroplasty for
             primary surgical management of idiopathic osteoarthritis.

          6. Patients who in the opinion of the Clinical Investigator are considered to be suitable
             for treatment with a fixed or mobile bearing knee system and who are suitable for
             patella resurfacing.

        Exclusion Criteria:

          1. Patients who, in the opinion of the Investigator, have an existing condition that
             would compromise their participation and follow-up in this study.

          2. Patients who require revision total knee arthroplasty surgery.

          3. Patients with any tibial deformity requiring tibial component augmentation.

          4. Patients whom, in the opinion of the Clinical Investigator, require a constrained
             prosthesis.

          5. Patients with Rheumatoid Arthritis.

          6. Patients with a pathology which, in the opinion of the Clinical Investigator, will
             adversely affect healing.

          7. Patients with other disorders which, in the opinion of the Clinical Investigator, will
             / could impair rehabilitation.

          8. Contra-indications for use of the device, as detailed in the package insert.

          9. Women who are pregnant.

         10. Subjects who are known drug or alcohol abusers or with psychological disorders that
             could effect follow-up care or treatment outcomes.

         11. Subjects who are currently involved in another clinical study with an investigational
             product.

         12. Subjects who are currently involved in any injury litigation claims.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>June 5, 2015</results_first_submitted>
  <results_first_submitted_qc>June 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2016</results_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>754 subjects were consented into the study, however only 720 received study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PFC Fixed Bearing PCL Sacrificed</title>
          <description>Fixed bearing
P.F.C Sigma Fixed Bearing Total knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="P2">
          <title>PFC Mobile Bearing PCL Sacrificed</title>
          <description>Mobile bearing
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="P3">
          <title>PFC Fixed Bearing PCL Retained</title>
          <description>Fixed bearing
P.F.C Sigma Fixed Bearing Total knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="P4">
          <title>PFC Mobile Bearing PCL Retained</title>
          <description>Mobile bearing
P.F.C Sigma Mobile Bearing Total knee system: Orthopaedic implant for total knee replacement</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="170"/>
                <participants group_id="P4" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Revision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsurfaced to Resurfaced Patella</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does not wish to Continue in Study</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mis-Randomized</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received treatment and were not mis-randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>PFC Fixed Bearing PCL Sacrificed</title>
          <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="B2">
          <title>PFC Sigma RP PCL Sacrificed</title>
          <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="B3">
          <title>PFC Sigma Fixed Bearing PCL Retained</title>
          <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="B4">
          <title>PFC Sigma RP PCL Retained</title>
          <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="170"/>
            <count group_id="B4" value="161"/>
            <count group_id="B5" value="683"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.8" spread="8.16"/>
                    <measurement group_id="B2" value="70.2" spread="7.60"/>
                    <measurement group_id="B3" value="70.1" spread="7.88"/>
                    <measurement group_id="B4" value="69.2" spread="8.59"/>
                    <measurement group_id="B5" value="69.8" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="161"/>
                    <measurement group_id="B5" value="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
        <time_frame>1 year</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 168 subjects in the PFC Sigma Fixed Bearing and 167 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 168 subjects in the PFC Sigma Fixed Bearing and 167 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.8" spread="13.41"/>
                    <measurement group_id="O2" value="108.4" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
        <time_frame>1 year</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 158 subjects in the PFC Sigma Fixed Bearing and 155 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 158 subjects in the PFC Sigma Fixed Bearing and 155 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.6" spread="12.94"/>
                    <measurement group_id="O2" value="101.6" spread="12.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
        <time_frame>Change from pre-op to 1 year</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 164 subjects in the PFC Sigma Fixed Bearing and 164 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 164 subjects in the PFC Sigma Fixed Bearing and 164 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="17.17"/>
                    <measurement group_id="O2" value="12.3" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
        <time_frame>Change from pre-op to 1 year</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 158 subjects in the PFC Sigma Fixed Bearing and 153 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 158 subjects in the PFC Sigma Fixed Bearing and 153 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="15.83"/>
                    <measurement group_id="O2" value="8.1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Range of Motion From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 156 subjects in the PFC Sigma Fixed Bearing and 148 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Range of Motion From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 156 subjects in the PFC Sigma Fixed Bearing and 148 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="15.81"/>
                    <measurement group_id="O2" value="12.0" spread="17.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Range of Motion From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Range of Motion From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="14.74"/>
                    <measurement group_id="O2" value="10.2" spread="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Range of Motion From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 123 subjects in the PFC Sigma Fixed Bearing and 124 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Range of Motion From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Range of motion is knee flexion (how far the patient can bend their knee) minus knee extension (how far the patient can straighten their knee). The result of this subtraction is the range of motion (bending and straightening) for that knee.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 123 subjects in the PFC Sigma Fixed Bearing and 124 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="15.46"/>
                    <measurement group_id="O2" value="14.5" spread="18.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Oxford Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 145 subjects in the PFC Sigma Fixed Bearing and 138 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Oxford Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 145 subjects in the PFC Sigma Fixed Bearing and 138 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.1" spread="8.35"/>
                    <measurement group_id="O2" value="-17.6" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Oxford Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 134 subjects in the PFC Sigma Fixed Bearing and 118 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Oxford Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 134 subjects in the PFC Sigma Fixed Bearing and 118 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.8" spread="9.93"/>
                    <measurement group_id="O2" value="-18.1" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Oxford Knee Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 114 subjects in the PFC Sigma Fixed Bearing and 111 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Oxford Knee Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The Oxford Knee Score (OKS) is a 12 to 60 point patient reported outcome (PRO) score (where 12 indicates the best outcome) that evaluates the affected knee. The total score is composed of Pain and Function.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 114 subjects in the PFC Sigma Fixed Bearing and 111 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="10.33"/>
                    <measurement group_id="O2" value="-19.9" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in American Knee Society Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 154 subjects in the PFC Sigma Fixed Bearing and 143 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in American Knee Society Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 154 subjects in the PFC Sigma Fixed Bearing and 143 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" spread="18.66"/>
                    <measurement group_id="O2" value="56.8" spread="18.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in American Knee Society Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 152 subjects in the PFC Sigma Fixed Bearing and 143 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in American Knee Society Knee Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 152 subjects in the PFC Sigma Fixed Bearing and 143 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" spread="21.02"/>
                    <measurement group_id="O2" value="49.5" spread="24.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in American Knee Society Knee Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 122 subjects in the PFC Sigma Fixed Bearing and 120 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in American Knee Society Knee Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>American Knee Society (AKS) knee score is a 0-100 point score (where 100 indicates excellent knee condition) that evaluates the affected knee. The knee score is composed of Pain, Range of Motion, and Stability.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 122 subjects in the PFC Sigma Fixed Bearing and 120 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="19.42"/>
                    <measurement group_id="O2" value="55.6" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in American Knee Society Function Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 155 subjects in the PFC Sigma Fixed Bearing and 144 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in American Knee Society Function Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 155 subjects in the PFC Sigma Fixed Bearing and 144 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="22.18"/>
                    <measurement group_id="O2" value="26.1" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in American Knee Society Function Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 154 subjects in the PFC Sigma Fixed Bearing and 146 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in American Knee Society Function Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 154 subjects in the PFC Sigma Fixed Bearing and 146 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="22.51"/>
                    <measurement group_id="O2" value="23.6" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in American Knee Society Function Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 124 subjects in the PFC Sigma Fixed Bearing and 125 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in American Knee Society Function Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>American Knee Society (AKS) function score is a 0-100 point score (where 100 indicates excellent knee function) that evaluates the affected knee. The function score is composed of walking and stair climbing ability.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 124 subjects in the PFC Sigma Fixed Bearing and 125 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="24.54"/>
                    <measurement group_id="O2" value="20.5" spread="22.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
        <time_frame>2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
        <time_frame>2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
        <time_frame>2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
        <time_frame>2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in SF-12 Physical Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 130 subjects in the PFC Sigma Fixed Bearing and 118 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in SF-12 Physical Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 130 subjects in the PFC Sigma Fixed Bearing and 118 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.38" spread="11.23"/>
                    <measurement group_id="O2" value="10.96" spread="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in SF-12 Physical Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 139 subjects in the PFC Sigma Fixed Bearing and 130 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in SF-12 Physical Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 139 subjects in the PFC Sigma Fixed Bearing and 130 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.47" spread="10.76"/>
                    <measurement group_id="O2" value="9.68" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in SF-12 Physical Health Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 107 subjects in the PFC Sigma Fixed Bearing and 109 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in SF-12 Physical Health Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 107 subjects in the PFC Sigma Fixed Bearing and 109 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" spread="11.84"/>
                    <measurement group_id="O2" value="8.75" spread="12.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in SF-12 Mental Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 130 subjects in the PFC Sigma Fixed Bearing and 118 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in SF-12 Mental Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 130 subjects in the PFC Sigma Fixed Bearing and 118 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="10.71"/>
                    <measurement group_id="O2" value="1.91" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in SF-12 Mental Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 139 subjects in the PFC Sigma Fixed Bearing and 130 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in SF-12 Mental Health Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 139 subjects in the PFC Sigma Fixed Bearing and 130 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="12.69"/>
                    <measurement group_id="O2" value="0.26" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in SF-12 Mental Health Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 107 subjects in the PFC Sigma Fixed Bearing and 109 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in SF-12 Mental Health Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The 12-Item Short Form Health Survey (SF-12) is a patient reported outcome survey that represents overall subjective health status by measuring eight health-related parameters (each scored from 0 [poor health] to 100 [better health]): body pain, general mental health, perception of general health, physical functioning, role limitations caused by mental condition, role limitations caused by a physical condition, social functioning, and vitality. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-12) and Mental Component Score (MCS-12).</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 107 subjects in the PFC Sigma Fixed Bearing and 109 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="12.74"/>
                    <measurement group_id="O2" value="1.98" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 152 subjects in the PFC Sigma Fixed Bearing and 141 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 152 subjects in the PFC Sigma Fixed Bearing and 141 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="6.89"/>
                    <measurement group_id="O2" value="8.4" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 153 subjects in the PFC Sigma Fixed Bearing and 144 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 153 subjects in the PFC Sigma Fixed Bearing and 144 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="7.14"/>
                    <measurement group_id="O2" value="9.7" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 122 subjects in the PFC Sigma Fixed Bearing and 122 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 122 subjects in the PFC Sigma Fixed Bearing and 122 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="7.04"/>
                    <measurement group_id="O2" value="8.6" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
        <time_frame>2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
        <time_frame>2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With at Least 1 Tibial Radiolucency Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Tibial Radiolucency observes a radiolucent line (of 0.5mm or wider) on the radiograph around the tibial component.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Lateral Release Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Lateral release is a surgical procedure to release tight capsular structures (lateral retinaculum) on the outside of the kneecap (patella). It is performed during knee surgery and allows the kneecap to move smoothly in the center of the knee. Rate information was collected at time of study surgery.</description>
        <time_frame>Operative</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Lateral Release Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Lateral release is a surgical procedure to release tight capsular structures (lateral retinaculum) on the outside of the kneecap (patella). It is performed during knee surgery and allows the kneecap to move smoothly in the center of the knee. Rate information was collected at time of study surgery.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Lateral Release Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Lateral release is a surgical procedure to release tight capsular structures (lateral retinaculum) on the outside of the kneecap (patella). It is performed during knee surgery and allows the kneecap to move smoothly in the center of the knee. Rate information was collected at time of study surgery.</description>
        <time_frame>Operative</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Lateral Release Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Lateral release is a surgical procedure to release tight capsular structures (lateral retinaculum) on the outside of the kneecap (patella). It is performed during knee surgery and allows the kneecap to move smoothly in the center of the knee. Rate information was collected at time of study surgery.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
        <time_frame>2 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="95.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.3" lower_limit="94.7" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
        <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
        <time_frame>2 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Sigma Fixed Bearing PCL Retained</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Retained</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm</title>
          <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 170 subjects in the PFC Sigma Fixed Bearing and 161 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="95.9" upper_limit="99.9"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.3" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
        <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Survivorship Analysis Results Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm</title>
          <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 176 subjects in the PFC Sigma Fixed Bearing and 176 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="92.0" upper_limit="98.3"/>
                    <measurement group_id="O2" value="97.6" lower_limit="93.7" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
        <time_frame>2 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
        <time_frame>2 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With No Anterior Knee Pain Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Anterior Knee Pain is assessed by the patient into 1 of 4 categories: None, Mild, Moderate, or Severe. The percentage of participants with no anterior knee pain is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
        <time_frame>2 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
        <time_frame>2 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 89 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
        <time_frame>5 Years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects With Good Quadriceps Strength Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>Quadriceps Strength is assessed by the patient into 1 of 3 categories: Good, Fair, or Poor. The percentage of participants with good quadriceps strength is reported in the data table.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 88 subjects in the PFC Sigma Fixed Bearing and 87 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 75 subjects in the PFC Sigma Fixed Bearing and 71 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 75 subjects in the PFC Sigma Fixed Bearing and 71 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="7.03"/>
                    <measurement group_id="O2" value="9.4" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
        <time_frame>Change from pre-op to 2 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 77 subjects in the PFC Sigma Fixed Bearing and 70 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Patella Score From Pre-op to 2 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 77 subjects in the PFC Sigma Fixed Bearing and 70 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="6.72"/>
                    <measurement group_id="O2" value="7.5" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 60 subjects in the PFC Sigma Fixed Bearing and 62 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups With Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 60 subjects in the PFC Sigma Fixed Bearing and 62 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="7.35"/>
                    <measurement group_id="O2" value="9.1" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
        <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
        <time_frame>Change from pre-op to 5 years</time_frame>
        <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 62 subjects in the PFC Sigma Fixed Bearing and 60 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PFC Fixed Bearing PCL Sacrificed</title>
            <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
          </group>
          <group group_id="O2">
            <title>PFC Sigma RP PCL Sacrificed</title>
            <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Change in Patella Score From Pre-op to 5 Years Between Sigma RP and Sigma Fixed Bearing Treatment Groups Without Patella Resurfacing in the PCL Sacrificing Arm</title>
          <description>The Patella Score is completed by the clinicians and assesses the anterior knee pain, quadriceps strength, ability to rise from a chair and stair climbing. The Patella Score ranges from 3 to 30 points with higher scores indicating better functionality and lower scores indicating poorer functionality.</description>
          <population>Due to consent withdrawals, deaths, lost to follow up, revisions, subjects whose patella were resurfaced, mis-randomized, those who did not wish to continue in the study, and incomplete or unavailable assessments, 62 subjects in the PFC Sigma Fixed Bearing and 60 subjects in the PFC Sigma RP Treatment Groups were available for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="6.57"/>
                    <measurement group_id="O2" value="8.1" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PFC Fixed Bearing PCL Sacrificed</title>
          <description>PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="E2">
          <title>PFC Sigma RP PCL Sacrificed</title>
          <description>PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="E3">
          <title>PFC Sigma Fixed Bearing PCL Retained</title>
          <description>PFC Sigma Fixed Bearing Total Knee System with PCL Retained
P.F.C Sigma Fixed Bearing total knee system: Orthopaedic implant for total knee replacement</description>
        </group>
        <group group_id="E4">
          <title>PFC Sigma RP PCL Retained</title>
          <description>PFC Sigma Rotating Platform Total Knee System with PCL Retained
P.F.C Sigma RP Mobile Bearing knee system: Orthopaedic implant for total knee replacement</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="96" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiac disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Heart enlarged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ischaemic Heart Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Faeces pale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hiatal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Death- Unknown</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Device connection issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Device extrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Weight bearing difficulty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Device component issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain and discomfort NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Surgical failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Stitch abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ear infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ear injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Glaucoma traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint dislocation postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fractured olecranon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Periorbital contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bone scan</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Endoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastrointestinal examination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Computerised tomogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Macular reflex abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint crepitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain groin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Stiff knees</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Back disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint lock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Musculoskeletal deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Osteosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain in elbow</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pain in hand</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Toe osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bladder neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lung metastases</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Prostatic neoplasms malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Brain secondaries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pituitary tumor NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bone Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Liver Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tethered cord syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dysgraphia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cold Sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ankle arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Wound drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Breast lump removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Post thrombotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>DePuy reserves the right to review the contents of publications in advance.The PI may freely disclose the trial results only after DePuy has been given the opportunity of reviewing the proposed results communications at least 30 days prior to the intended release.DePuy will advise the PI of any perceived errors,omissions or corrections but the PI will retain final editorial control.In case of disagreement,DePuy and the PI will make every effort to meet in order to discuss and resolve any issues.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Dwyer, Ph.D, CCRA</name_or_title>
      <organization>DePuy International</organization>
      <email>kdwyer2@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

